Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
DexCom, Inc. - Common Stock
(NQ:
DXCM
)
63.00
+0.20 (+0.32%)
Streaming Delayed Price
Updated: 10:25 AM EDT, Apr 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about DexCom, Inc. - Common Stock
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
47
48
Next >
DexCom: Revenue Up, EPS Misses Mark
↗
February 13, 2025
DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short.
Via
The Motley Fool
DexCom’s (NASDAQ:DXCM) Q4: Beats On Revenue
February 13, 2025
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 7.6% year on year to $1.11 billion. The company expects the full year’s...
Via
StockStory
Topics
Artificial Intelligence
Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations
↗
February 13, 2025
Dexcom stock fell late Thursday after the company missed fourth-quarter profit expectations by a nickel per share.
Via
Investor's Business Daily
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
February 13, 2025
From
DexCom, Inc.
Via
Business Wire
Earnings Scheduled For February 13, 2025
↗
February 13, 2025
Via
Benzinga
DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect
February 12, 2025
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know.
Via
StockStory
Should You Buy DexCom Stock Before Feb. 13?
↗
February 06, 2025
Via
The Motley Fool
Deep Dive Into DexCom Stock: Analyst Perspectives (5 Ratings)
↗
February 03, 2025
Via
Benzinga
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?
↗
February 10, 2025
Based on a technical and fundamental analysis of NASDAQ:DXCM we can say: DEXCOM INC (NASDAQ:DXCM)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via
Chartmill
Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade
↗
February 03, 2025
Via
The Motley Fool
Got $2,000? 2 Top Growth Stocks to Buy and Hold for Years
↗
February 03, 2025
Via
The Motley Fool
For those who appreciate growth without the sticker shock, NASDAQ:DXCM is worth considering.
↗
January 31, 2025
NASDAQ:DXCM is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Via
Chartmill
Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.
January 30, 2025
From
DexCom, Inc.
Via
Business Wire
Expert Outlook: DexCom Through The Eyes Of 11 Analysts
↗
January 16, 2025
Via
Benzinga
Is NASDAQ:DXCM on the Verge of a Major Breakout as a Strong Growth Stock?
↗
January 16, 2025
Exploring the Growth Potential of DEXCOM INC (NASDAQ:DXCM) as It Nears a Breakout.
Via
Chartmill
Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday
↗
January 16, 2025
Via
Benzinga
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
January 16, 2025
Via
Benzinga
2 Healthcare Stocks to Buy Hand Over Fist in January
↗
January 16, 2025
Via
The Motley Fool
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
January 13, 2025
From
DexCom, Inc.
Via
Business Wire
NASDAQ:DXCM qualifies as a high growth stock and is consolidating.
↗
December 25, 2024
DEXCOM INC (NASDAQ:DXCM) qualifies as a high growth stock and is consolidating.
Via
Chartmill
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
↗
December 21, 2024
Via
The Motley Fool
Peering Into DexCom's Recent Short Interest
↗
December 16, 2024
Via
Benzinga
Key Takeaways From DexCom Analyst Ratings
↗
December 09, 2024
Via
Benzinga
Health Tracking Is Moving To Smart Rings From Watches. Oura Leads Market.
↗
January 09, 2025
Smart rings are one of the hottest consumer electronics categories, as evidenced by exhibitors at CES 2025. Oura leads the market.
Via
Investor's Business Daily
3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
↗
January 08, 2025
Via
The Motley Fool
Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025
From
DexCom, Inc.
Via
Business Wire
These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
↗
January 04, 2025
Via
The Motley Fool
DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM
December 21, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
December 17, 2024
From
DexCom, Inc.
Via
Business Wire
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
↗
December 02, 2024
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
47
48
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.